Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program
Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program
January 8, 2024 at 8:00 AM EST
Financial Update
- Fourth quarter revenue of
$135.4 million , a 31 percent increase
over the same period in 2022 - Full year 2023 revenue of
$482.4 million , a 20 percent increase over 2022 - 2024 revenue guidance of
$600 –$630 million - Cash and investments of
$425.4 million as ofDecember 31, 2023 - Announcement of
$200 million stock repurchase program
“As the true prevalence of hypercortisolism and its devastating impact become better understood, physicians are identifying and treating more patients with Cushing’s syndrome than ever before. Our 2023 commercial results reflect strong, nationwide growth in the number of patients receiving Korlym and the number of physicians prescribing the medication. We are confident that rates of screening and treatment will continue to increase. We are providing 2024 revenue guidance of
Corcept’s fourth quarter 2023 revenue was
The company announced a program to repurchase up to
About Corcept’s Stock Repurchase Program
Our Board of Directors has approved a program authorizing the repurchase of up to
About
For over 25 years, Corcept’s focus on cortisol modulation and its potential to treat patients across a wide variety of serious disorders has led to the discovery of more than 1,000 proprietary selective cortisol modulators. Corcept’s advanced clinical trials are being conducted in patients with hypercortisolism, solid tumors, ALS and NASH. In
Forward-Looking Statements
Statements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations that are subject to risks and uncertainties that might cause our actual results to differ materially from those such statements express or imply. These risks and uncertainties include, but are not limited to, our ability to operate our business; generate sufficient revenue to fund our activities; the availability of competing treatments for hypercortisolism, including generic versions of Korlym; our ability to obtain acceptable prices and adequate insurance coverage and reimbursement for Korlym; risks related to the development of relacorilant, dazucorilant, miricorilant and our other product candidates, including their clinical attributes, regulatory approvals, mandates, oversight and other requirements; the timing, cost and outcome of legal disputes and investigations; and the scope and protective power of our intellectual property. These and other risks are set forth in our
In this press release, forward-looking statements include: our preliminary, unaudited, fourth quarter and full year 2023 financial results, which are subject to adjustment and may differ materially from our audited financial results; 2024 revenue guidance; increasing screening for and medical treatment of hypercortisolism; and the size, duration and intended funding sources of our stock repurchase program. We disclaim any intention or duty to update forward-looking statements made in this press release.
CONTACT:
Investor inquiries:
ir@corcept.com
Media inquiries:
Communications@corcept.com
www.corcept.com
Source: Corcept Therapeutics Incorporated